CoChat

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation

Open access
Yu, Lijian, Kim, Haesook T., Kasar, Siddha N., Benien, Parul, Du, Wei, Hoang, Kevin, Aw, Andrew, Tesar, Bethany, Improgo, Reina, Fernandes, Stacey M., Radhakrishnan, Saranya, Klitgaard, Josephine L., Lee, Charles, Getz, Gad, Setlur, Sunita R., Brown, Jennifer R. · 2017 · Clinical Cancer Research
Cited by 95

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: Chronic lymphocytic leukemia (CLL) with 17p deletion typically progresses quickly and is refractory to most conventional therapies. However, some del(17p) patients do not progress for years, suggesting that del(17p) is not the only driving event in CLL progression. We hypothesize that other concomitant genetic abnormalities underlie the clinical heterogeneity of del(17p) CLL. Experimental Design: We profiled the somatic mutations and copy number alterations (CNA) in a large group of del(17p) CLLs as well as wild-type CLL and analyzed the genetic basis of their clinical heterogeneity. Results: We found that increased somatic mutation number associates with poor overall survival independent of 17p deletion (P = 0.003). TP53 mutation was present in 81% of del(17p) CLL, mostly clonal (82%), and clonal mutations with del(17p) exhibit shorter overall survival than subclonal mutations with del(17p) (P = 0.019). Del(17p) CLL has a unique driver mutation profile, including NOTCH1 (15%), RPS15 (12%), DDX3X (8%), and GPS2 (6%). We found that about half of del(17p) CLL cases have recurrent deletions at 3p, 4p, or 9p and that any of these deletions significantly predicts shorter overall survival. In addition, the number of CNAs, but not somatic mutations, predicts shorter time to treatment among patients untreated at sampling. Indolent del(17p) CLLs were characterized by absent or subclonal TP53 mutation and few CNAs, with no difference in somatic mutation number. Conclusions: We conclude that del(17p) has a unique genomic profile and that clonal TP53 mutations, 3p, 4p, or 9p deletions, and genomic complexity are associated with shorter overall survival. Clin Cancer Res; 23(3); 735–45. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-0594

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 95

Metadata

Authors
Yu, L., Kim, H. T., Kasar, S. N., Benien, P., Du, W., Hoang, K., Aw, A., Tesar, B., Improgo, R., Fernandes, S. M., Radhakrishnan, S., Klitgaard, J. L., Lee, C., Getz, G., Setlur, S. R., & Brown, J. R.
Venue
Clinical Cancer Research
Published
2017-01-31
Volume
23
Issue
3
Pages
735-745
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2507865108
Cited by
95
References
5
FWCI
7.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0594
The paper
Yu, L., Kim, H. T., Kasar, S. N., Benien, P., Du, W., Hoang, K., Aw, A., Tesar, B., Improgo, R., Fernandes, S. M., Radhakrishnan, S., Klitgaard, J. L., Lee, C., Getz, G., Setlur, S. R., & Brown, J. R. (2017). Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0594

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.